Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 286 AL 300

YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease

Muszyński P, Groblewska M, Kulczyńska-Przybik A, Kułakowska A, Mroczko B.

Curr Neuropharmacol. 2017;15(6):906-917. doi: 10.2174/1570159X15666170208124324.

Effect of a Comprehensive Intervention on Plasma BDNF in Patients with Alzheimer's Disease

Balietti M, Giuli C, Fattoretti P, Fabbietti P, Papa R, Postacchini D, Conti F.

J Alzheimers Dis. 2017;57(1):37-43. doi: 10.3233/JAD-161168.

A second wind for the cholinergic system in Alzheimer's therapy

Douchamps V, Mathis C.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):112-123. doi: 10.1097/FBP.0000000000000300.

Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid

Bloniecki V, Aarsland D, Blennow K, Cummings J, Falahati F, Winblad B, Freund-Levi Y.

J Alzheimers Dis. 2017;57(2):387-393. doi: 10.3233/JAD-160758.

Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment

Hane FT, Robinson M, Lee BY, Bai O, Leonenko Z, Albert MS.

J Alzheimers Dis. 2017;57(3):645-665. doi: 10.3233/JAD-160907.

Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial

Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, Dahl D, Caulder E, Neth B, Montine TJ, Jung Y, Maldjian J, Whitlow C, Friedman S.

J Alzheimers Dis. 2017;57(4):1325-1334. doi: 10.3233/JAD-161256.

A phase 3 trial of IV immunoglobulin for Alzheimer disease

Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2017 May 2;88(18):1768-1775. doi: 10.1212/WNL.0000000000003904. Epub 2017 Apr 5.

Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease

Kasai T, Kondo M, Ishii R, Tanaka A, Ataka S, Shimada H, Tomiyama T, Mori H, Taylor M, Allsop D, Nakagawa M, Mizuno T, Tokuda T.

PLoS One. 2017 Apr 10;12(4):e0174630. doi: 10.1371/journal.pone.0174630. eCollection 2017.

Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer's Disease Phase IIa and Expanded Access Trials

Nelson TJ, Sun MK, Lim C, Sen A, Khan T, Chirila FV, Alkon DL.

J Alzheimers Dis. 2017;58(2):521-535. doi: 10.3233/JAD-170161.

Plasma REST: a novel candidate biomarker of Alzheimer's disease is modified by psychological intervention in an at-risk population

Ashton NJ, Hye A, Leckey CA, Jones AR, Gardner A, Elliott C, Wetherell JL, Lenze EJ, Killick R, Marchant NL.

Transl Psychiatry. 2017 Jun 6;7(6):e1148. doi: 10.1038/tp.2017.113.

Characterizing Alzheimer's disease through metabolomics and investigating anti-Alzheimer's disease effects of natural products

Yi L, Liu W, Wang Z, Ren D, Peng W.

Ann N Y Acad Sci. 2017 Jun;1398(1):130-141. doi: 10.1111/nyas.13385. Epub 2017 Jun 20.

Potential Roles of Exosomal MicroRNAs as Diagnostic Biomarkers and Therapeutic Application in Alzheimer's Disease

Chen JJ, Zhao B, Zhao J, Li S.

Neural Plast. 2017;2017:7027380. doi: 10.1155/2017/7027380. Epub 2017 Jul 9.

miRNAs in Alzheimer Disease - A Therapeutic Perspective

Gupta P, Bhattacharjee S, Sharma AR, Sharma G, Lee SS, Chakraborty C.

Curr Alzheimer Res. 2017;14(11):1198-1206. doi: 10.2174/1567205014666170829101016.

[Alzheimer's disease from Auguste Deter to the present : Progress, disappointments and open questions]

Pantel J.

Z Gerontol Geriatr. 2017 Oct;50(7):576-587. doi: 10.1007/s00391-017-1307-2. Epub 2017 Sep 18.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias